Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (561-570 of 636) with videos related to

Pageof 64
Sort By:
Journal of Hepatology|December 13, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisLung-Yi Mak, Ed Gane, Christian Schwabe, et al.
The American Journal of Gastroenterology|October 3, 2022
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 ParticipantsPhoebe Wen Lin Tay, Cheng Han Ng, Snow Yunni Lin, et al.
European Radiology|April 26, 2021
Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosisYali Qu, Michael S Middleton, Rohit Loomba, et al.
Journal of Hepatology|November 11, 2022
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitisWei Shen, Michael S Middleton, Guilherme M Cunha, et al.
Nature Medicine|July 21, 2025
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitisMaximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2023
Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metforminRebecca W Zeng, Jie Ning Yong, Darren J H Tan, et al.
Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
Nature Communications|January 20, 2024
Discovery of a peripheral 5HT<sub>2A</sub> antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitisHaushabhau S Pagire, Suvarna H Pagire, Byung-Kwan Jeong, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trialsRish K Pai, David E Kleiner, John Hart, et al.
Communications Medicine|October 30, 2024
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteriaLuis Antonio Díaz, Jeffrey V Lazarus, Eduardo Fuentes-López, et al.
Pageof 64

Showing results (561-570 of 636) with videos related to

Sort By:
Pageof 64
Journal of Hepatology|December 13, 2022
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisLung-Yi Mak, Ed Gane, Christian Schwabe, et al.
The American Journal of Gastroenterology|October 3, 2022
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 ParticipantsPhoebe Wen Lin Tay, Cheng Han Ng, Snow Yunni Lin, et al.
European Radiology|April 26, 2021
Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosisYali Qu, Michael S Middleton, Rohit Loomba, et al.
Journal of Hepatology|November 11, 2022
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitisWei Shen, Michael S Middleton, Guilherme M Cunha, et al.
Nature Medicine|July 21, 2025
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitisMaximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2023
Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metforminRebecca W Zeng, Jie Ning Yong, Darren J H Tan, et al.
Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
Nature Communications|January 20, 2024
Discovery of a peripheral 5HT<sub>2A</sub> antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitisHaushabhau S Pagire, Suvarna H Pagire, Byung-Kwan Jeong, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trialsRish K Pai, David E Kleiner, John Hart, et al.
Communications Medicine|October 30, 2024
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteriaLuis Antonio Díaz, Jeffrey V Lazarus, Eduardo Fuentes-López, et al.
Pageof 64